WO2007095156A3 - Taste masking of aerosolized fluoroquinolones - Google Patents

Taste masking of aerosolized fluoroquinolones Download PDF

Info

Publication number
WO2007095156A3
WO2007095156A3 PCT/US2007/003649 US2007003649W WO2007095156A3 WO 2007095156 A3 WO2007095156 A3 WO 2007095156A3 US 2007003649 W US2007003649 W US 2007003649W WO 2007095156 A3 WO2007095156 A3 WO 2007095156A3
Authority
WO
WIPO (PCT)
Prior art keywords
taste masking
fluoroquinolones
formulations
bacterial infections
aerosolized fluoroquinolones
Prior art date
Application number
PCT/US2007/003649
Other languages
French (fr)
Other versions
WO2007095156A2 (en
Inventor
Mark Surber
Keith Bostian
Olga Lomovskaya
David Griffith
Mike Dudley
Original Assignee
Mpex Pharmaceuticals Inc
Mark Surber
Keith Bostian
Olga Lomovskaya
David Griffith
Mike Dudley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mpex Pharmaceuticals Inc, Mark Surber, Keith Bostian, Olga Lomovskaya, David Griffith, Mike Dudley filed Critical Mpex Pharmaceuticals Inc
Priority to BRPI0707904A priority Critical patent/BRPI0707904A8/en
Publication of WO2007095156A2 publication Critical patent/WO2007095156A2/en
Publication of WO2007095156A3 publication Critical patent/WO2007095156A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
PCT/US2007/003649 2006-02-13 2007-02-12 Taste masking of aerosolized fluoroquinolones WO2007095156A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BRPI0707904A BRPI0707904A8 (en) 2006-02-13 2007-02-12 GUSTATORY DISGUSTATION OF AEROSOLIZED FLUOROQUINOLONES

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US77330106P 2006-02-13 2006-02-13
US77330006P 2006-02-13 2006-02-13
US60/773,301 2006-02-13
US60/773,300 2006-02-13
US11/436,875 US7838532B2 (en) 2005-05-18 2006-05-18 Aerosolized fluoroquinolones and uses thereof
US11/436,875 2006-05-18

Publications (2)

Publication Number Publication Date
WO2007095156A2 WO2007095156A2 (en) 2007-08-23
WO2007095156A3 true WO2007095156A3 (en) 2007-12-21

Family

ID=38230310

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/003649 WO2007095156A2 (en) 2006-02-13 2007-02-12 Taste masking of aerosolized fluoroquinolones

Country Status (3)

Country Link
US (1) US7838532B2 (en)
BR (1) BRPI0707904A8 (en)
WO (1) WO2007095156A2 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005110022A2 (en) 2004-05-17 2005-11-24 Corus Pharma, Inc. Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US7838532B2 (en) 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US20070219223A1 (en) * 2006-03-07 2007-09-20 Endacea, Inc. Compositions and methods for treating respiratory disorders
WO2008116165A2 (en) * 2007-03-21 2008-09-25 Next Safety, Inc. Methods and systems of delivering medication via inhalation
EP2152304B1 (en) * 2007-05-02 2018-08-22 The Regents of the University of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US8513305B2 (en) 2007-05-14 2013-08-20 Research Foundation Of State University Of New York Induction of a physiological dispersion response in bacterial cells in a biofilm
WO2009136408A1 (en) * 2008-04-09 2009-11-12 Institute Of Life Sciences Synergistic pharmaceutical cocrystals
AU2009302478B2 (en) 2008-10-07 2015-09-03 Horizon Orphan Llc Aerosol fluoroquinolone formulations for improved pharmacokinetics
ES2809177T3 (en) 2008-10-07 2021-03-03 Horizon Orphan Llc Inhalation of levofloxacin to reduce lung inflammation
US20110238602A1 (en) * 2008-11-13 2011-09-29 Azouri Ilan Ovadia Method for enhanced marketing of vibration medicine products and coaching therefrom
WO2010096242A1 (en) * 2009-02-18 2010-08-26 Aradigm Corporation Ph-modulated formulations for pulmonary delivery
CA2754691C (en) 2009-03-26 2019-07-30 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
MY178871A (en) 2009-04-24 2020-10-21 Raptor Pharmaceuticals Inc Methods of treating a pulmonary bacterial infection using fluoro-quinolones
CN102711760A (en) * 2009-08-19 2012-10-03 Mpex医药有限公司 Use of aerosolized antibiotics for treating chronic obstructive pulmonary disease
EP2467715A4 (en) * 2009-08-19 2013-01-16 Mpex Pharmaceuticals Inc Riboflavin based aerosol and use as placebo in trials
CN101627999B (en) * 2009-08-20 2011-05-04 山东罗欣药业股份有限公司 Balofloxacin composition, preparation method thereof and synthesis method of material medicament
CA2938650C (en) 2009-09-04 2018-01-09 Raptor Pharmaceuticals Inc. Use of aerosolized levofloxacin for treating cystic fibrosis
WO2011094504A2 (en) * 2010-01-28 2011-08-04 Ora, Inc. Antimicrobial sinus irrigation compositions, methods, and devices
CN103200938B (en) 2010-08-30 2018-07-31 普马特里克斯营业公司 Dried powder formula and method for treating pulmonary disease
EP2464346A1 (en) 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
WO2012030513A2 (en) * 2010-08-30 2012-03-08 Cempra Pharmaceuticals Inc. Methods of treating bacterial infections through pulmonary delivery of fusidic acid
AU2011314007B2 (en) 2010-09-29 2017-01-19 Pulmatrix, Inc. Cationic dry powders
EP4008326A1 (en) 2010-09-29 2022-06-08 Pulmatrix Operating Company, Inc. Monovalent metal cation dry powders for inhalation
EP2670242B1 (en) 2011-01-31 2022-03-16 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
WO2013112865A1 (en) * 2012-01-27 2013-08-01 The Trustees Of The University Of Pennsylvania Diagnosis and treatment for respiratory tract diseases
CA2865972C (en) 2012-02-29 2022-01-04 Pulmatrix, Inc. Inhalable dry powders
EP2833867B2 (en) * 2012-04-04 2023-05-10 Intervet International B.V. Solid oral pharmaceutical compositions for isoxazoline compounds
ES2959198T3 (en) 2012-07-24 2024-02-21 Avalyn Pharma Inc Pirfenidone and pyridone analogues in aerosol
CA2904388C (en) * 2013-03-08 2023-09-26 Research Institute At Nationwide Children's Hospital Transcutaneous dosage formulation
WO2014141218A1 (en) * 2013-03-15 2014-09-18 Università Degli Studi Di Milano - Bicocca Novel 1, 2, 4-oxadiazol compounds active against gram-positive pathogens
CA2907566C (en) 2013-04-01 2023-08-22 Pulmatrix, Inc. Tiotropium dry powders
US20140377357A1 (en) * 2013-06-19 2014-12-25 Professional Compounding Centers Of America Poloxamer Based Inhalation Composition
CA3172586A1 (en) 2013-07-31 2015-02-05 Avalyn Pharma Inc. Aerosol imatininb compounds and uses thereof
NZ760541A (en) 2014-01-10 2022-08-26 Avalyn Pharma Inc Aerosol pirfenidone and pyridone analog compounds and uses thereof
KR20190075168A (en) * 2014-04-08 2019-06-28 필립모리스 프로덕츠 에스.에이. Nicotine formulations and methods of making the same
EP3266445B1 (en) 2015-03-02 2022-05-11 Takeda Pharmaceutical Company Limited Suspension or composition containing nano-cocrystal and manufacturing method therefor
CN111110641B (en) * 2018-10-31 2022-03-01 长春海悦药业股份有限公司 Levofloxacin tablet composition and preparation method thereof
CN109679503B (en) * 2018-12-28 2021-01-08 中山市天图精细化工有限公司 Pet cake curing aerosol
EP3980032A1 (en) 2019-06-04 2022-04-13 Thirty Respiratory Limited Methods and compositions for generating nitric oxide and uses thereof to deliver nitric oxide via the respiratory tract
CA3142101A1 (en) 2019-06-04 2020-12-10 Thirty Holdings Limited Methods and compositions for generating nitric oxide and uses thereof
BR112022021436A2 (en) 2020-04-23 2023-01-17 Thirty Respiratory Ltd METHODS AND COMPOSITIONS FOR TREATMENT AND COMBATING TUBERCULOSIS
WO2021214440A1 (en) 2020-04-23 2021-10-28 Thirty Respiratory Limited Nitric oxide or nitric oxide releasing compositions for use in treating sars-cov and sars-cov-2
CN112957322B (en) * 2021-03-23 2023-08-15 回音必集团江西东亚制药有限公司 Levofloxacin lactate sodium chloride injection and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072102A1 (en) * 2001-03-05 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Taste masked liquid pharmaceutical compositions
US20030028025A1 (en) * 2001-06-20 2003-02-06 Raghavan Krishnaswamy S. Pediatric formulation of gatifloxacin
WO2004019912A2 (en) * 2002-08-29 2004-03-11 Novadel Pharma Inc. Buccal, polar or non-polar spray or capsule containing drugs for treating an infectious disease or cancer
WO2005089738A2 (en) * 2004-03-17 2005-09-29 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4730000A (en) * 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
DK170473B1 (en) * 1985-06-20 1995-09-11 Daiichi Seiyaku Co S (-) - pyridobenzoxazinforbindelser
DE3704907A1 (en) * 1987-02-17 1988-08-25 Bayer Ag TOPICALLY APPLICABLE PREPARATIONS OF GYRASE INHIBITORS IN COMBINATION WITH CORTICOSTEROIDS
ES2102393T3 (en) * 1989-12-29 1997-08-01 Abbott Lab QUINOLONE ACID COMPLEXES CARBOXYLIC - METAL ION - ACID.
FR2665635A1 (en) * 1990-08-10 1992-02-14 Merck Sharp & Dohme FLUID PHARMACEUTICAL COMPOSITION BASED ON METAL COMPLEX AND PROCESS FOR PREPARING THE SAME.
US5258528A (en) * 1990-11-30 1993-11-02 Warner-Lambert Company Individual stereoisomers of pyrrolidine methanamines substituted on the ring nitrogen by a 1-phenylethyl group
DK0656206T3 (en) 1991-06-10 2001-10-08 Schering Corp Aerosol formulations without chlorofluorocarbon compounds
IT1250691B (en) * 1991-07-22 1995-04-21 Giancarlo Santus THERAPEUTIC COMPOSITIONS FOR INTRANASAL ADMINISTRATION INCLUDING KETOROLAC.
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
CA2176298C (en) * 1995-06-27 2009-01-27 Dennis D. Copeland A single high dose fluoroquinolone treatment
US6579854B1 (en) * 1996-08-14 2003-06-17 Vanderbilt University Diagnosis and management of infection caused by chlamydia
US6838552B1 (en) * 1997-08-14 2005-01-04 Vanderbilt University Diagnosis and management of infection caused by Chlamydia
US6406880B1 (en) * 1997-05-02 2002-06-18 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
US6664239B2 (en) * 1997-05-06 2003-12-16 Vanderbilt University Diagnosis and management of infection caused by Chlamydia
US6756369B2 (en) * 1997-05-06 2004-06-29 Vanderbilt University Diagnosis and management of infection caused by Chlamydia
US6884784B1 (en) * 1997-05-06 2005-04-26 Vanderbilt University Diagnosis and management of infection caused by chlamydia
US6890526B2 (en) * 1997-05-06 2005-05-10 Vanderbilt University Methods and reagents for the treatment of multiple sclerosis
US20010044584A1 (en) * 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
ID21415A (en) * 1997-12-05 1999-06-10 Upjohn Co QUINOLON MAGNESIUM ANTIBIOTIC COMPOUNDS
GB9810299D0 (en) 1998-05-15 1998-07-15 Glaxo Group Ltd Use of nitric oxide synthase inhibitors
CN1133432C (en) * 1998-08-21 2004-01-07 千寿制药株式会社 Aqueous liquid preparations
BR9914051A (en) * 1998-09-25 2001-06-19 Cubist Pharm Inc Methods for administering antibiotics
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
CA2282066C (en) * 1999-06-29 2010-09-07 Smithkline Beecham Corporation Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
PT1666028E (en) * 1999-10-29 2010-06-15 Novartis Ag Dry powder compositions having improved dispersivity
US6294178B1 (en) * 1999-11-01 2001-09-25 Robert E. Weinstein Method and device for coordinating topical and oral sinusitis treatments
US6962151B1 (en) * 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
US20010049366A1 (en) * 2000-02-09 2001-12-06 Alcon Universal Ltd. Topical solution formulations containing an antibiotic and a corticosteroid
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6663890B2 (en) * 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Metronidazole antibiotic product, use and formulation thereof
US6730320B2 (en) * 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
US6669948B2 (en) * 2000-02-24 2003-12-30 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6663891B2 (en) * 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Erythromyacin antibiotic product, use and formulation thereof
US6667057B2 (en) * 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Levofloxacin antibiotic product, use and formulation thereof
US6667042B2 (en) * 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Fluroquinilone antibiotic product, use and formulation thereof
US6608078B2 (en) * 2000-05-08 2003-08-19 Wockhardt Limited Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment
US6716819B2 (en) * 2000-05-19 2004-04-06 University Of Iowa Research Foundation Use of xylitol to reduce ionic strength and activate endogenous antimicrobials for prevention and treatment of infections
PE20020044A1 (en) * 2000-06-16 2002-01-30 Upjohn Co THIAZINE OXAZOLIDINONE
US6492328B2 (en) * 2000-06-28 2002-12-10 The University Of Iowa Research Foundation Novispirins: antimicrobial peptides
AU8298801A (en) * 2000-07-26 2002-02-05 John K Vyden Methods for treating atopic disorders
AU2001286852A1 (en) 2000-08-29 2002-03-13 Chiron Corporation Quinoline antibacterial compounds and methods of use thereof
ATE319710T1 (en) * 2000-12-21 2006-03-15 Pharmacia & Upjohn Co Llc ANTIMICROBIAL QUINOLOONE DERIVATIVES AND THEIR USE FOR TREATING BACTERIAL INFECTIONS
US6878713B2 (en) * 2001-04-25 2005-04-12 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US20030138403A1 (en) * 2001-06-29 2003-07-24 Maxygen Aps Interferon formulations
SI1273292T1 (en) * 2001-07-02 2004-12-31 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
WO2003051300A2 (en) * 2001-12-13 2003-06-26 Activbiotics, Inc. Metal complexes and formulations of rifamycin analogues and uses therof
US20030171340A1 (en) * 2002-02-07 2003-09-11 Jenefir Isbister Methods of disease treatment using metal-complexed tetracycline antibiotics
WO2003075889A1 (en) 2002-03-05 2003-09-18 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
US7607436B2 (en) * 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
US20040045546A1 (en) * 2002-09-05 2004-03-11 Peirce Management, Llc Pharmaceutical delivery system for oral inhalation through nebulization consisting of inert substrate impregnated with substance (S) to be solubilized or suspended prior to use
US20040152701A1 (en) * 2002-12-02 2004-08-05 Dr. Reddy's Laboratories Limited Novel anhydrous crystalline form of Levofloxacin and process for preparation there of
WO2004055025A1 (en) * 2002-12-16 2004-07-01 Ranbaxy Laboratories Limited Pure levofloxacin hemihydrate and processes for preparation thereof
MXPA05007466A (en) * 2003-01-09 2006-03-08 Arizeke Pharmaceuticals Inc Methods of treating lung diseases.
EP1660094A4 (en) * 2003-08-26 2009-09-16 Univ Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
US8375947B2 (en) * 2003-11-17 2013-02-19 Novartis Ag Introducing aerosol into a ventilator
US7148404B2 (en) * 2004-05-04 2006-12-12 Novozymes A/S Antimicrobial polypeptides
EP1758920A1 (en) * 2004-05-21 2007-03-07 Mpex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors and methods of treating bacterial infections
US7632869B2 (en) * 2004-05-24 2009-12-15 Bausch & Lomb Incorporated Antimicrobial compositions and uses thereof
MXPA06015220A (en) * 2004-06-21 2007-12-13 Nektar Therapeutics Compositions comprising amphotericin b.
MX2007000759A (en) 2004-07-22 2007-03-28 Pfizer Prod Inc Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form.
WO2006033713A2 (en) 2004-08-09 2006-03-30 Chiron Corporation Methods for ciprofloxacin inhalation
US7388077B2 (en) * 2004-11-12 2008-06-17 Novozymes A/S Polypeptides having antimicrobial activity and polynucleotides encoding the same
WO2006078925A2 (en) 2005-01-21 2006-07-27 Warner Chilcott Company, Inc. A tetracycline metal complex in a solid dosage form
EP1871910A4 (en) * 2005-04-05 2009-07-29 Scripps Research Inst Compositions and methods for enhancing drug sensitivity and treating drug resistant infections an diseases
RS55114B1 (en) 2005-05-18 2016-12-30 Raptor Pharmaceuticals Inc Aerosolized fluoroquinolones and uses thereof
US7838532B2 (en) 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
CN101212990A (en) * 2005-07-01 2008-07-02 金文申有限公司 Medical devices comprising a reticulated composite material
CA2632028A1 (en) * 2005-12-14 2007-06-21 Activbiotics, Inc. Rifamycin analogs and uses thereof
WO2007085057A1 (en) 2006-01-25 2007-08-02 The Council Of The Queensland Institute Of Medical Research A medical protocol
WO2007090123A2 (en) 2006-01-30 2007-08-09 University Of Chicago Mgra is a redox regulator of antibiotic sensitivity and virulence
ES2671342T3 (en) * 2006-02-10 2018-06-06 Pari Pharma Gmbh Nebulized antibiotics for inhalation therapy
US20090264342A1 (en) 2006-02-13 2009-10-22 Trustees Of Boston University Compositions and methods for antibiotic potentiation and drug discovery
US20070197548A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone compositions
WO2008025560A1 (en) 2006-09-01 2008-03-06 Pari Pharma Gmbh Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072102A1 (en) * 2001-03-05 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Taste masked liquid pharmaceutical compositions
US20030028025A1 (en) * 2001-06-20 2003-02-06 Raghavan Krishnaswamy S. Pediatric formulation of gatifloxacin
WO2004019912A2 (en) * 2002-08-29 2004-03-11 Novadel Pharma Inc. Buccal, polar or non-polar spray or capsule containing drugs for treating an infectious disease or cancer
WO2005089738A2 (en) * 2004-03-17 2005-09-29 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors

Also Published As

Publication number Publication date
WO2007095156A2 (en) 2007-08-23
BRPI0707904A8 (en) 2017-05-02
US20060276483A1 (en) 2006-12-07
US7838532B2 (en) 2010-11-23
BRPI0707904A2 (en) 2011-05-17

Similar Documents

Publication Publication Date Title
WO2007095156A3 (en) Taste masking of aerosolized fluoroquinolones
WO2006125132A3 (en) Aerosolized fluoroquinolones and uses thereof
WO2007067520A3 (en) Lipid-based compositions of antiinfectives for treating pulmonary infections
WO2009086470A3 (en) Aerosolized nitrite and nitric oxide - donating compounds and uses thereof
MX345158B (en) Aerosol fluoroquinolone formulations for improved pharmacokinetics.
WO2006108556A3 (en) Pharmaceutical aerosol composition
MX2008010222A (en) Nebulised antibiotics for inhalation therapy.
WO2005102431A3 (en) Aerosol delivery apparatus for pressure assisted breathing
CA2824432C (en) Aerosol pirfenidone and pyridone analog compounds and uses thereof
NO20054180L (en) Treatment of bacterial diseases of the respiratory tract by local administration of fluoroquinolones
WO2008000483A3 (en) Phenol derivatives for the treatment of respiratory diseases
WO2005110022A3 (en) Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections
WO2012016889A3 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
WO2006087543A8 (en) Antibacterial piperidine derivatives
WO2006086107A3 (en) Methods and compositions for minimizing accrual of inhalable insulin in the lungs
WO2007008825A3 (en) System and method for optimized delivery of an aerosol to the respiratory tract
WO2008020227A3 (en) Antibacterial pyrrolecarboxamides
YU36302A (en) Novel tiotropium preparation -containing inhalation powder
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
WO2002069945A3 (en) Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors
HK1089359A1 (en) Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
WO2005063777A8 (en) Benzylphosphate and substituted benzylphosphate prodrugs for the treatment of pulmonary inflammation
MY159377A (en) Aqueous suspensions of ciclesonide for nebulisation
WO2009047788A3 (en) Topical composition containing the combination of mupirocin and beclomethasone
NZ547276A (en) Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07750482

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: PI0707904

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080812